162070-61-3

Usage

Uses

Used in Pharmaceutical Industry:
(E)-α-Methyl-β-[[4-[2-(MethylaMino)ethoxy]phenyl]phenylMethylene]benzeneethanol is used as a pharmaceutical compound for its potential therapeutic effects. The presence of the aminoethoxy group and the phenylmethylene bridge may contribute to its interaction with biological targets, making it a candidate for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, (E)-α-Methyl-β-[[4-[2-(MethylaMino)ethoxy]phenyl]phenylMethylene]benzeneethanol can be utilized as a starting material or intermediate for the synthesis of more complex molecules. Its unique structure and functional groups make it a valuable tool for exploring new chemical reactions and developing novel compounds with specific properties.
Used in Material Science:
(E)-α-Methyl-β-[[4-[2-(MethylaMino)ethoxy]phenyl]phenylMethylene]benzeneethanol may also find applications in material science, particularly in the development of new materials with specific properties. Its structural features and functional groups could be exploited to create materials with tailored characteristics, such as improved stability, reactivity, or selectivity.

Upstream product

• 19076-79-0 (E/Z)-1-Bromo-2-[4-[2-(dimethylamino)ethoxy]phenyl]-1,2-diphenylethene 
• 97151-02-5 (E)-(+/-)-alpha-Hydroxytamoxifen 
• 75-07-0 acetaldehyde 
• 265321-58-2 (E/Z)-1-Bromo-2-[4-(2-methylaminoethoxy)phenyl]-1,2-diphenylethene 
• 288617-57-2 (E)-4-{4-[2-(N-Ethoxycarbonyl-N-methylamino)ethoxy]phenyl}-3,4-diphenyl-3-buten-2-ol 

Downstream Products

• 288617-58-3 (E)-4-{4-[2-(N-Benzyloxycarbonyl-N-methylamino)ethoxy]phenyl}-3,4-diphenyl-3-buten-2-ol 
• 288617-59-4 (E)-2-Acetoxy-4-{4-[2-(N-benzyloxycarbonyl-N-methylamino)ethoxy]phenyl}-3,4-diphenyl-3-butene 
• 288617-60-7 (E)-2-Acetoxy-4-{4-[2-(methylamino)ethoxy]phenyl}-3,4-diphenyl-3-butene 
• 743458-14-2 9-{(2R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-tetrahydro-furan-2-yl}-2-{(E)-1-methyl-3-[4-(2-methylamino-ethoxy)-phenyl]-2,3-diphenyl-allylamino}-1,9-dihydro-purin-6-one 
• 743458-11-9 (2-{4-[(E)-3-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-1,2-diphenyl-but-1-enyl]-phenoxy}-ethyl)-methyl-carbamic acid benzyl ester 
• 743458-12-0 {2-[4-((E)-3-Amino-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-methyl-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Characterization of the major DNA adduct formed by α-hydroxy-N- desmethyltamoxifen in vitro and in vivo

Tamoxifen is hepatocarcinogenic in rats and has been associated with an increased risk of endometrial cancer in women. Recent reports suggest that it may be genotoxic in humans. N-Desmethyltamoxifen is a major tamoxifen metabolite that has been proposed to be responsible for one of the major adducts detected in liver DNA of rats treated with tamoxifen. The metabolic activation of N-desmethyltamoxifen to DNA binding products may involve oxidation to α-hydroxy-N-desmethyltamoxifen followed by esterification. In the study presented here, we report the synthesis of α-hydroxy-N- desmethyltamoxifen and the characterization of the major adduct obtained from α-sulfoxy-N-desmethyltamoxifen in vitro as (E)-α-(deoxyguanosin-N2-yl)-N- desmethyltamoxifen. In addition, we use 32P-postlabeling in combination with HPLC to compare the adducts formed in the livers of female Sprague- Dawley rats treated by gavage with tamoxifen or equimolar doses of α- hydroxy-N-desmethyltamoxifen. We conclude that one of the major adducts formed in vivo and previously suggested to derive from N-desmethyltamoxifen is chromatographically identical to α-(deoxyguanosin-N2-yl)-N- desmethyltamoxifen.

Identification of tamoxifen-DNA adducts induced by α-acetoxy-N-desmethyltamoxifen

Treatment with tamoxifen increased the risk of endometrial cancers in breast cancer patients and women participating in the chemoprevention study. In our laboratory, tamoxifen-DNA adducts, including α-(N2-deoxyguanosinyl)tamoxifen (dG-N2-TAM), were detected in the endometrium of women taking tamoxifen [Shibutani, S., et al. (1999) Chem. Res. Toxicol. 12, 646-653]. On the basis of recent animal studies, deoxyguanosinyl-N-desmethyltamoxifen (dG-N-desmethylTAM) adducts are also suspected to be formed in the liver. In the study presented here, we synthesized α-acetoxy-N-desmethyltamoxifen as a model activated metabolite of N-desmethyltamoxifen. The overall yield of α-acetoxy-N-desmethyltamoxifen from α-hydroxy-tamoxifen was approximately 42%. α-Acetoxy-N-desmethyltamoxifen was highly reactive to 2'-deoxyguanosine, as was similarly observed for tamoxifen α-sulfate. The two reaction products were identified as a mixture of epimers of the trans form or cis form of α-(N2-deoxyguanosinyl)-N-desmethyltamoxifen (dG-N2-N-desmethylTAM) by mass and proton magnetic resonance spectroscopy. In addition, the trans and cis forms of dG 3'-monophosphate-N2-N-desmethylTAM were prepared as standard markers for 32P-postlabeling/HPLC analysis. Using this technique, dG-N2-N-desmethylTAM adducts were detected in calf thymus DNA reacted with α-acetoxy-N-desmethyltamoxifen.